Digital illustration of a DNA strand fusing with glowing AI circuitry inside a futuristic lab, symbolizing Absci’s generative AI drug discovery technology.

Absci: When AI Meets Antibodies — and Insiders Can’t Resist Buying More!

AI is designing drugs, and Absci is leading the charge — with insider confidence, top-tier partners, and a cash runway through 2028. Still pre-revenue but packed with promise, this biotech might just be the next NVIDIA of antibodies.

Read entire article

Cartoon illustration of Illumina headquarters glowing under a DNA-shaped light beam, with a stock chart climbing in the background and two executives holding shopping bags labeled

🔬 Illumina (ILMN): Let’s Illuminate the Bull Case!

After losing nearly 80% of its value since 2021, Illumina (ILMN) may be ready for a glow-up. CEO Jacob Thaysen and CFO Ankur Dhingra just bought big, and institutional holders are still hanging on. What do they see—and should you see it too?

Read entire article